Most clinical antibiotics are derived from actinomycete natural products 19 (NPs) discovered at least 60 years ago. Repeated rediscovery of known compounds 20 led the pharmaceutical industry to largely discard microbial NPs as a source of new 21 chemical diversity but advances in genome sequencing revealed that these organisms 22 have the potential to make many more NPs than previously thought. Approaches to 23 unlock NP biosynthesis by genetic manipulation of the strain, by the application of 24 chemical genetics, or by microbial co-cultivation have resulted in the identification of 25 new antibacterial compounds. Concomitantly, intensive exploration of coevolved 26 ecological niches, such as insect-microbe defensive symbioses, has revealed these 27 to be a rich source of chemical novelty. Here we report the novel lanthipeptide 28 antibiotic kyamicin generated through the activation of a cryptic biosynthetic gene 29 2 cluster identified by genome mining Saccharopolyspora species found in the obligate 30 domatia-dwelling ant Tetraponera penzigi of the ant plant Vachellia drepanolobium. 31 Heterologous production and purification of kyamicin allowed its structural 32 characterisation and bioactivity determination. Our activation strategy was also 33 successful for the expression of lantibiotics from other genera, paving the way for a 34 synthetic heterologous expression platform for the discovery of lanthipeptides that are 35 not detected under laboratory conditions or that are new to nature.
The external, cuticular microbiome of T. penzigi ants is heterogeneous, and unbiased 80 methods have shown this is dominated by members of the phyla Proteobacteria and 81 Firmicutes, with Actinobacteria forming a minor component (13) . This contrasts with 82 the better studied fungus-farming leafcutter ants of the tribe Attini, which are 83 dominated by actinobacteria, specifically by a single strain of Pseudonocardia that can 84 be vertically transmitted by the new queens (18, 19) . Leafcutter ants feed cut plant 85 material to their symbiotic food fungus Leucoagaricus gongylophorus and use 86 antifungals made by their Pseudonocardia symbionts to defend their food fungus 87 against fungal parasites in the genus Escovopsis (20) (21) (22) . Despite the low abundance 88 of actinobacteria, we isolated several strains, including three from the rare 89 actinomycete genus Saccharopolyspora, which, despite the modest number of 90 described species, is the origin of the medically and agriculturally important natural 91 products erythromycin and spinosyn. 92 Genome mining of these Saccharopolyspora strains identified a conserved BGC 93 encoding a putative cinnamycin-like lanthipeptide antibiotic (lantibiotic) (23), although 94 no products for this BGC could be identified from the wild-type isolates. Cinnamycin is 95 a class II type B lantibiotic produced by Streptomyces cinnamoneus DSM 40005 which 96 destabilises the cytoplasmic membrane by binding phosphatidylethanolamine (PE) 97 (23) (24) (25) . Lanthipeptides belong to the ribosomally synthesised and post-translationally 98 modified peptide (RiPP) family of natural products (26, 27) , and cinnamycin is the 99 founding member of a sub-group of lanthipeptide RiPPs with antibacterial activity that 100 includes cinnamycin B (28), duramycin (29), duramycin B and C (30) , and molecule which we named kyamicin (Fig. 1B) . The sequence and annotations for 144 these three BGCs have been deposited at GenBank under the accession numbers 145 MK251551 (KY3), MK251552 (KY7) and MK251553 (KY21). 146 Through comparison to the cinnamycin BGC (24), and cinnamycin biosynthesis (32), 147 we assigned roles to each of the genes in the kyamicin (kya) BGC (Table 1 ). The kya 148 BGC is more compact than that for cinnamycin, and the genes missing from the 149 kyamicin BGC are dispensable for cinnamycin production (38) . The cinorf11 gene is 150 not required for cinnamycin production but a homologue is present in the kyamicin 151 cluster. While cinorf11 lacks a plausible stop codon and its reading frame extends 570 152 bp into the cinR1 gene, its homologue, kyaorf11, has a stop codon and does not run 153 into the kyaR1 gene suggesting it may encode a functional protein.
154
To detect production of kyamicin we grew all three strains on a range of 13 liquid media 155 (Table S2 ) and extracted after four, five, six and seven days of growth, using 156 (individually) methanol and ethyl acetate. Analysis of the extracts using UPLC/MS 157 failed to identify the anticipated product (the methods were validated using authentic 158 duramycin). This was consistent with parallel bioassays which failed to show any 159 antibacterial activity for the extracts against Bacillus subtilis EC1524, which is sensitive 160 to cinnamycin (24). Similarly, no activity was observed in overlay bioassays.
161
Activation of the kyamicin BGC. Cinnamycin production and self-immunity 162 ultimately rely on two gene products (38). The transcription of the biosynthetic genes 163 is driven by CinR1, a SARP (Streptomyces Antibiotic Regulatory Protein, which usually 164 act as pathway specific transcription activators), and self-immunity is conferred by a 165 methyl transferase (Cinorf10) that modifies PE in the membrane to prevent binding of 166 cinnamycin. We reasoned that transcription of the homologues of these two genes 167 (kyaR1 and kyaL, respectively), driven by a constitutive promoter, would circumvent 168 the natural regulatory mechanism and initiate production of kyamicin. To achieve this, 169 we made a synthetic construct, pEVK1, containing kyaR1-kyaL (in that order), with a 170 NdeI site overlapping the start codon of kyaR1, a HindIII site after the stop codon of 171 the kyaL and with the kyaN ribosome binding site (RBS) located between the two 172 genes (the kyaN RBS was chosen as its sequence is most similar in the BGC to that 173 of an ideal RBS) (Fig. S2A ). The kyaR1-kyaL cassette was cloned into pGP9 (39) to 174 yield pEVK4 which was introduced into the three Saccharopolyspora strains by conjugation. This resulted in single copies of the plasmid integrated at the φBT1 phage 176 integration site of each strain. Exconjugants were assayed by overlaying with B. 177 subtilis EC1524, revealing zones of clearing for all three strains containing pEVK4 (Fig. 178 2A, Fig. S3 ). For the KY21 ex-conjugant, agar plugs were taken from the zone of 179 clearing, extracted with 5% formic acid and analysed by UPLC/MS ( Fig. 2A) we cloned kyaR1L as a NdeI/HindIII fragment into pIJ10257, a φBT1-based integrative 187 expression vector with a hygromycin resistance marker (41); this yielded pEVK6, 188 which has the constitutive ermE* promoter driving expression of kyaR1L. We then 
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Having established the production of kyamicin in the M1152 heterologous host, we 203 used this system to better understand how each gene product contributes to the 204 activation of kyamicin biosynthesis. We cloned kyaL and kyaR1 separately into 205 pIJ10257, to give pEVK12 and pEVK13, respectively. Each plasmid was then 206 introduced into M1152 alongside pWDW63, and doubly antibiotic resistant ex-207 conjugants were selected. These were grown on R5 agar plates and overlaid with B. subtilis EC1524; agar plugs were extracted from the resulting bioassay plates as 209 before. For M1152/pEVK12 (kyaL only) no growth inhibition of the bioassay strain was 210 observed and we could not detect kyamicin or deoxykyamicin using UPLC/MS. For 211 M1152/pEVK13 (kyaR1 only), we observed a zone of inhibition which was 212 approximately three times smaller than for the M1152/pEVK6 (kyaR1L) positive 213 control. UPLC/MS analysis of the M1152/pEVK13 strain detected only deoxykyamicin 214 ( Fig. S4 ). This is consistent with previous work which reported that deoxy versions of 215 lantibiotics have lower biological activity (43).
216
Isolation, structure elucidation and bioactivity. To isolate and verify the structure 217 of kyamicin, growth of S. coelicolor M1152/pEVK6/pWDW63 was scaled up in liquid 218 culture and the cell pellet extracted with 50% methanol. Crude extracts were further 219 purified using semi-preparative HPLC to yield pure kyamicin (2.5 mg).
220
As the methyllanthionine bridges of kyamicin limit the ability to induce fragmentation 221 in MS/MS experiments, the lantibiotic was subjected to chemical reduction with 222 NaBH4-NiCl2 using a procedure published previously for the related molecule duramycin using the spot-on-lawn method. The minimum inhibitory concentration 241 (MIC) of kyamicin against B. subtilis EC1524 was 128 μg/mL, whereas duramycin 242 inhibited at 32 μg/mL and cinnamycin at 16 μg/mL, representing a 4 and 8-fold MIC 243 increase respectively (Fig. 4 ).
244
Cross species activation of the duramycin BGC. Many cinnamycin-like BGCs can 245 be identified in the published sequence databases, but their products remain cryptic.
246
Thus, the potential of the kyaR1-kyaL construct to induce expression of other 247 cinnamycin-like lantibiotics was explored.
248
The BGC for duramycin was cloned previously from Streptomyces cinnamoneus 249 ATCC 12686 ( Fig. S7A ) but attempts to produce the lantibiotic heterologously failed.
250
Consequently, the duramycin BGC was reconfigured in pOJKKH, which contains all 251 the biosynthetic genes, but lacks immunity and regulatory genes, and has a SARP 252 binding site upstream of durN that is similar to that upstream of kyaN ( Fig. S7B) (38) . 253 pOJKKH and pEVK6 were introduced sequentially into S. coelicolor M1152 via 254 conjugation and the resulting ex-conjugants assessed for duramycin production. Table 2 ). The production of duramycin was confirmed by comparison to 260 an authentic standard. A deoxy derivative was also detected with an m/z of 998.93 261 ( Despite culturing on a wide range of media, we were unable to elicit production of 279 kyamicin in the wild-type Saccharopolyspora strains. The production of cinnamycin in 280 S. cinnamoneus DSM 40005 requires the expression of two key genes, cinR1 and 281 cinorf10, encoding a pathway specific regulatory gene (a SARP) and a self-immunity 282 gene (a PE methyltransferase), respectively (38). As the kya BGC encodes 283 homologues of these genes, we expressed them constitutively in the three 284 Saccharopolyspora strains which led to activation of the BGC and production of 285 kyamicin. Since we were unable to isolate enough kyamicin from these strains for 286 further study, a heterologous production platform was developed using S. coelicolor 287 M1152 which allowed us to confirm the structure of kyamicin and assess its 288 antibacterial activity.
289
Having demonstrated the utility of a constitutively expressed SARP/self-immunity 290 cassette for driving expression of the otherwise silent kya BGC we utilised this 291 knowledge to activate duramycin production in a heterologous host.
292
Contemporaneous with our experiments, the duramycin BGC was also identified by 293 genome sequencing of S. cinnamoneus ATCC 12686 (33). This analysis described 294 the same genomic region containing durN to durH and surrounding genes (Table 1) 295 but failed to reveal putative regulatory and immunity genes. Co-expression of durA, 296 durM, durN and durX in E. coli was sufficient to direct the biosynthesis of duramycin section of low mol %GC DNA, the analysis of which suggests that a phage or other 304 mobile element may have inserted between durZ and durorf8 (Fig. S7 ). Thus, it 305 appears likely that the immunity and regulatory mechanisms described previously for 306 the control of cinnamycin biosynthesis are conserved for duramycin biosynthesis in S. 307 cinnamoneus ATCC 12686.
308
Given the potential utility of cinnamycin-like class II lanthipeptides in several 309 therapeutic contexts, the ability to generate analogues of these compounds with 310 modified properties and in sufficient quantity for preclinical assessment is of significant 311 value. The methods described here provide a platform for the identification of 
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317
Bacterial strains, plasmids and growth conditions. All bacterial strains and 318 plasmids used in this study are listed in Table S1 in the supplemental material.
319
Saccharopolyspora and Streptomyces strains were grown on soya flour mannitol 320 (SFM) agar medium with appropriate antibiotics at 30 °C unless otherwise stated. E. 321 coli and B. subtilis EC1524 strains were grown on lysogeny broth (LB) medium with 322 appropriate antibiotics at 37 °C. R5 agar (44) was used for bioassay plates.
323
DNA extraction and genomic analysis. The salting out method (44) was used to 324 extract genomic DNA. The DNA was sequenced at the Earlham Institute (Norwich, 325 UK) using SMRT sequencing technology (Pacific Biosciences RSII platform) and 326 assembled using the HGAP2 pipeline (36).
327
Overlay bioassays. For each strain to be tested, a streak from a spore stock was 328 applied in the centre of an R5 agar plate and left to grow for seven days. B. subtilis 329 EC1524 was grown from a single colony overnight, then diluted 1:20 in fresh media 330 and grown until OD600 = 0.4 -0.6. The exponential culture was mixed with 1:100 molten 331 soft nutrient agar (SNA) (44) and the mixture was used to overlay the plate (5 mL SNA 332 mixture/agar plate). The plate was incubated at room temperature overnight.
Extractions from overlay bioassays. Plugs of agar 6.35 mm in diameter were taken 334 adjacent to the streaked actinomycete strain on an overlay bioassay plate, 335 corresponding to the zone of growth inhibition where one was observed. Agar plugs 336 were frozen at -80 °C for 10 min, thawed and then 300 μL of 5% formic acid was 337 added. This was vortexed briefly and shaken for 20 min. After centrifugation (15,682 338 × g for 15 min) the supernatant was collected and filtered using a filter vial (HSTL 339 Labs) prior to UPLC-MS analysis. (Fig. S2A) followed by colony hybridization to give pDWCC2 and pDWCC3, respectively.
374
Analysis of the sequence of these plasmids identified 15 genes (shown in Fig. S7) ) series for the complete peptide ( Figure S5 ).
496
Fragmentation of the lysinoalanine bridge (pink) occurred via rearrangement to give 497 N=CH 2 at the terminus of the lysine sidechain and a glycine residue at position 6. was generated by SnapGene Viewer (v4.2.11) . The difference between KY21 to 520 strains KY3 and KY7 is indicated with a black arrow and a box at position 685. Figure S5 ). Fragmentation of the lysinoalanine bridge (pink) occurred via rearrangement to give N=CH 2 at the terminus of the lysine sidechain and a glycine residue at position 6.
Reduction m/z = 899.36 m/z = 854.42 
